关键词：类风湿性关节炎；慢性疾病；炎症；关节组织周围；关节疼痛
摘 要：RA is a chronic disease that leads to inflammation and pain of joints, tissues that surround the joints, and other organs. It can occur at any age, even in children, which is known as juvenile arthritis. RA symptoms begin slowly, usually with mild pain around the joints coupled with stiffness and fatigue, and in the later stages it causes inflammation of the joints. The disease is three times more common in women than men. Genetic and environmental elements are known to contribute to the development of RA.
目 录：

01. Executive Summary

02. List of Abbreviations

03. Scope of the Report

03.1 Market Overview

03.2 Product Offerings

03.2.1 Product Profiles

04. Market Research Methodology

04.1 Market Research Process

04.2 Research Methodology

05. Introduction

06. Market Landscape

06.1 Market Overview

06.2 Market Size and Forecast

06.3 Five Forces Analysis

07. Competitive Assessment of Top Drugs

08. Market Segmentation by Treatment

Approach

09. Geographical Segmentation

10. Rate of Incidence and Prevalence

10.1.1 US

10.1.2 UK

10.1.3 Asia

11. Pipeline Snapshot

12. Buying Criteria

13. Market Growth Drivers

14. Drivers and their Impact

15. Market Challenges

16. Impact of Drivers and Challenges

17. Market Trends

18. Trends and their Impact

19. Vendor Landscape

19.1 Competitive Scenario

19.1.1 Key News

19.1.2 Mergers and Acquisitions

19.2 Market Share Analysis 2013

19.3 Other Prominent Vendors

20. Key Vendor Analysis

20.1 AbbVie

20.1.1 Key Facts

20.1.2 Business Description

20.1.3 Product Segmentation

20.1.4 Product Segmentation by Revenue 2013

20.1.5 Product Segmentation by Revenue 2012 and 2013

20.1.6 Geographical Segmentation by Revenue 2013

20.1.7 Business Strategy

20.1.8 Key Developments

20.1.9 SWOT Analysis

20.1.10 Strengths

20.1.11 Weaknesses

20.1.12 Opportunities

20.1.13 Threats

20.2 Amgen

20.2.1 Key Facts

20.2.2 Business Overview

20.2.3 Product Segmentation by Revenue 2013

20.2.4 Sales by Geographical Segmentation 2013

20.2.5 Business Strategy

20.2.6 Key Information

20.2.7 SWOT Analysis

20.2.8 Strengths

20.2.9 Weaknesses

20.2.10 Opportunities

20.2.11 Threats

20.3 Bristol-Myers Squibb

20.3.1 Key Facts

20.3.2 Business Overview

20.3.3 Product Segmentation

20.3.4 Sales by Geography

20.3.5 Business Strategy

20.3.6 Key Information

20.3.7 SWOT Analysis

20.3.8 Strengths

20.3.9 Weaknesses

20.3.10 Opportunities

20.3.11 Threats

20.4 F. Hoffmann-La Roche

20.4.1 Key Facts

20.4.2 Business Overview

20.4.3 Business Segmentation

20.4.4 Revenue by Business Segmentation 2012 and 2013

20.4.5 Sales by Geography

20.4.6 Business Strategy

20.4.7 Key Information

20.4.8 SWOT Analysis

20.4.9 Strengths

20.4.10 Weaknesses

20.4.11 Opportunities

20.4.12 Threats

20.5 Janssen Pharmaceuticals

20.5.1 Key Facts

20.5.2 Business Overview

20.5.3 Product Segmentation

20.5.4 Business Strategy

20.5.5 Recent Developments

20.5.6 SWOT Analysis

20.5.7 Strengths

20.5.8 Weaknesses

20.5.9 Opportunities

20.5.10 Threats

20.6 Pfizer

20.6.1 Key Facts

20.6.2 Business Overview

20.6.3 Business Segmentation by Revenue 2013

20.6.4 Business Segmentation by Revenue 2012 and 2013

20.6.5 Sales by Geography

20.6.6 Business Strategy

20.6.7 Key Developments

20.6.8 SWOT Analysis

20.6.9 Strengths

20.6.10 Weaknesses

20.6.11 Opportunities

20.6.12 Threats

21. Other Reports in this Series